Global Metabolic Disorders Therapeutics Market 2016-2020

Publisher Name :
Date: 27-Sep-2016
No. of pages: 163
Inquire Before Buying

About Metabolic Disorders

Metabolic disorders occur as a result of disruption of chemical processes and conversions occurring in the cells and fluids of the body. This is mainly because of defects in the enzyme; all process in the body are controlled by enzymes. Any disruption in the pathways involved in the development and metabolism of carbohydrates, proteins, fats, and nucleic acids, results in the development of metabolic disorders.

This analyst forecast the global metabolic disorders therapeutics market to grow at a CAGR of 4.62% during the period 2016-2020.

Covered in this report

This report covers the present scenario and the growth prospects of the global metabolic disorders therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment of various metabolic disorders including diabetes, obesity, lysosomal storage diseases, and hypercholesterolemia.

The market is divided into the following segments based on geography:

Americas

APAC

EMEA

The report, Global Metabolic Disorders Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

Novo Nordisk

Sanofi

Merck

AstraZeneca

Eli Lilly

Other prominent vendors

AbbVie

Actelion Pharmaceuticals

Adocia

Aegerion Pharmaceuticals

Akros Pharma

Alnylam Pharmaceuticals

Amarin

nAmgen

Amicus Therapeutics

Arbutus Biopharma

Arena Pharmaceuticals

Astellas Pharma

Atheronova

Aurobindo Pharma

Baxalta

Belrose Pharma

BHV Pharma

Biocon

Biodel

BioMarin

Bionaturis

Biosidus

Biospherics

Boehringer Ingelheim

Bristol-Myers Squibb

Catabasis Pharmaceuticals

Cerenis Therapeutics

Chipscreen Biosciences

Cipla

CJ HealthCare

CKD Bio

Concord Biotech

ConjuChem

CureDm

CymaBay Therapeutics

Daewoong

Daiichi Sankyo

Dance Biopharm

DiaMedica

Diamyd Therapeutics

Diasome Pharmaceuticals

DiaVacs

Dong-A ST

Eisai

Elcelyx Therapeutics

Esperion Therapeutics

Exsulin

F. Hoffmann-La Roche

Gan & Lee Pharmaceuticals

Generex Biotechnology

Genfit

GlaxoSmithKline

HanAll BioPharma

Hanmi Pharmaceutical Company

Hua Medicine

Iltoo Pharma

Intarcia Therapeutics

InteKrin Therapeutics

Intrexon

Ionis Pharmaceuticals

Islet Sciences

ISU Abxis

Janssen Pharmaceuticals

Japan Tobacco

JCR Pharmaceuticals

JW Pharmaceuticals

Kadmon Pharmaceuticals

Kamada

KinDex Pharmaceuticals

Kissei

Kotobuki

Kowa Company

Laboratoires SMB

Lexicon Pharmaceuticals

Ligand Pharmaceuticals

Living Cell Technologies

Livzon

LIXTE Biotechnology

Lupin

MacroGenics

Madrigal Pharmaceuticals

MannKind

MedImmune

Melior Pharmaceuticals

Merrion Pharmaceuticals

Merz Pharmaceuticals

Metabolic Solutions Development Company

Mitsubishi Tanabe Pharma

Mylan

Neothetics

Neuraltus Pharmaceuticals

NGM Biopharmaceuticals

NGM Biopharmaceuticals

Norgine BV

Novartis

NuSirt Biopharma

Oramed

Orexigen Therapeutics

Osiris Therapeutics

Peptron

Perle Biosciences

Pfizer

PhaseBio Pharmaceuticals

Poxel

Protalix Biotherapeutics

Raptor

Recordati

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

REGiMMUNE

Rhythm Pharmaceuticals

Saniona

Santaris Pharma

Santaris Pharma

Serometrix

Shionogi

Shire

Sigma-Tau

Sirona Biochem

Strongbridge Biopharma

SUN Pharma

Takeda

Teva

Thera technologies

Theracos

Toleranzia

Tolerion

Torrent Pharmaceuticals

Transition Therapeutics

UCB

Utrecht Holdings

VeroScience

Vivus

vTv Therapeutics

XBiotech

Xeris Pharmaceuticals

XOMA

Zafgen

Zydus Cadila

Market driver

Increase in academia-industry collaborations for drug development

For a full, detailed list, view our report

Market challenge

Low compliance and adherence rates

For a full, detailed list, view our report

Market trend

Increase in academia-industry collaborations for drug development

For a full, detailed list, view our report

Key questions answered in this report

What will the market size be in 2020 and what will the growth rate be?

What are the key market trends?

What is driving this market?

What are the challenges to market growth?

Who are the key vendors in this market space?

What are the market opportunities and threats faced by the key vendors?

What are the strengths and weaknesses of the key vendors?

Global Metabolic Disorders Therapeutics Market 2016-2020

Table of Contents

PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Pipeline portfolio
Pipeline portfolio: Global diabetes drugs market
Pipeline portfolio: Global hyperphosphatemia drugs market
Pipeline portfolio: Global anti-obesity drugs market
PART 06: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 07: Market segmentation by type of disease
Diabetes
Obesity
Hypercholesterolemia
Lysosomal storage diseases
PART 08: Global diabetes drugs market
Market overview
Global type 1 diabetes market
Global type 2 diabetes drugs market
Vendors in global diabetes drugs market
PART 09: Global hypercholesterolemia drugs market
Market overview
Vendors in global hypercholesterolemia drugs market
PART 10: Global lysosomal storage diseases market
Market overview
Vendors in global lysosomal storage disorders drugs market
PART 11: Global anti-obesity drugs market
Market overview
Vendors in global anti-obesity drugs market
PART 12: Geographical segmentation
Global metabolic disorders therapeutics market by geography 2015-2020
Metabolic disorders therapeutics market in Americas
Metabolic disorders therapeutics market in EMEA
Metabolic disorders therapeutics market in APAC
PART 13: Market drivers
Patient assistance programs
Special regulatory designations for rare diseases
Increase in academia-industry collaborations for drug development
PART 14: Impact of drivers
PART 15: Market challenges
Low compliance and adherence rates
High cost of therapies
Complex storage conditions and distribution policies for insulin
PART 16: Impact of drivers and challenges
PART 17: Market trends
Focus on oral insulin therapies
Strong and diversified pipeline portfolio
Strategic collaborations and acquisitions
PART 18: Vendor landscape
Competitive scenario
Other prominent vendors
PART 19: Key vendor analysis
Novo Nordisk
Sanof
Merck
AstraZeneca
Eli Lilly
PART 20: Appendix
List of abbreviations

List of Exhibits

Exhibit 01: Product offerings
Exhibit 02: Key buying criteria and customer segments for metabolic disorder drugsKey buying criteria for metabolic disorders drugs 2015
Exhibit 03: Impact of key customer segments on market 2015
Exhibit 04: Global metabolic disorders therapeutic market snapshot: Developed and emerging markets 2015
Exhibit 05: Global metabolic disorders therapeutics market 2015-2020 ($ billions)
Exhibit 06: Opportunity analysis: Global metabolic disorders therapeutics market
Exhibit 07: Global metabolic disorders therapeutics market: Growth cycle analysis
Exhibit 08: Five forces analysis
Exhibit 09: Global metabolic disorders therapeutics market by type of disease
Exhibit 10: Global metabolic disorders therapeutics market by type (2015-2020)
Exhibit 11: Global metabolic disorders therapeutics market n growth lifecycle analysis
Exhibit 12: Top selling diabetes drugs based on sales 2015 ($ billions)
Exhibit 13: Market share of global diabetes drugs in global pharmaceutical market 2015
Exhibit 14: Global diabetes drugs market 2015-2020 ($ billions)
Exhibit 15: Global type 1 diabetes market 2015-2020 ($ billions)
Exhibit 16: Global type 2 diabetes drugs market 2015-2020 ($ billions)
Exhibit 17: Market share analysis of vendors in global diabetes drugs market
Exhibit 18: Revenues from the sales of top five products in global diabetes drugs market 2013-2015 ($ billions)
Exhibit 19: Revenues from the sales of top five products in hypercholesterolemia drugs market 2013-2015 ($ billions)
Exhibit 20: Market dynamics of hypercholesterolemia drugs
Exhibit 21: Percentage share of hypercholesterolemia drugs by drug class 2015
Exhibit 22: Global hypercholesterolemia drugs market 2015-2020 ($ billions)
Exhibit 23: Market share analysis of global hypercholesterolemia drugs market 2015
Exhibit 24: Products offered by major vendors in global hypercholesterolemia drugs market
Exhibit 25: Global lysosomal storage diseases drugs market 2015-2020 ($ billions)
Exhibit 26: Key events in treatment of lysosomal storage diseases
Exhibit 27: Products offered by major vendors in global lysosomal storage disorders drugs market
Exhibit 28: Global anti-obesity drugs market 2015-2020 ($ millions)
Exhibit 29: Products offered by major vendors in global anti-obesity drugs market
Exhibit 30: Global metabolic disorders therapeutics market by geography 2015-2020
Exhibit 31: Global metabolic disorder therapeutics market by geography 2015 and 2020
Exhibit 32: Global metabolic disorder therapeutics market by geography 2015-2020 ($ billions)
Exhibit 33: Global share of metabolic disorder therapeutics market by geography 2015
Exhibit 34: Global share of various metabolic disorder therapeutics market by geography based on disease type 2015
Exhibit 35: Global metabolic disorders therapeutics market by region: Market growth lifecycle analysis 2015
Exhibit 36: Metabolic disorder therapeutics market in Americas 2015-2020 ($ billions)
Exhibit 37: Prevalence of obesity in various countries in Europe 2025
Exhibit 38: Metabolic disorders therapeutics market in EMEA 2015-2020 ($ billions)
Exhibit 39: Metabolic disorder therapeutics market in APAC 2015-2020 ($ billions)
Exhibit 40: Prevalence of diabetes in selected countries in APAC 2007 and 2025
Exhibit 41: Few metabolic disorder drugs with patient assistance programs
Exhibit 42: Impact of drivers
Exhibit 43: Impact of drivers and challenges
Exhibit 44: Oral insulin pipeline portfolio
Exhibit 45: Some investigational molecules for metabolic disorders and their mechanisms
Exhibit 46: Key vendors ranking 2015
Exhibit 47: Geographical presence of key vendors
Exhibit 48: Competitive scenario of global metabolic disorders therapeutics market vendors 2015-2020
Exhibit 49: Novo Nordisk: Profile
Exhibit 50: Novo Nordisk: Strength analysis
Exhibit 51: Novo Nordisk: Growth strategy matrix
Exhibit 52: Novo Nordisk: Growth opportunity assessment
Exhibit 53: Novo Nordisk: Business segmentation by revenue 2015
Exhibit 54: Novo Nordisk: Key products in diabetes and obesity care
Exhibit 55: Novo Nordisk: YoY growth and revenue generated from net product sales of human insulins 2012-2015 ($ billions)
Exhibit 56: Novo Nordisk: YoY growth and revenue generated from net product sales of Levemir 2012-2015 ($ billions)
Exhibit 57: Novo Nordisk: YoY growth and revenue of NovoRapid/ NovoLog 2012-2015 ($ billions)
Exhibit 58: Novo Nordisk: YoY growth and revenue of NovoMix/NovoLog Mix 2012-2015 ($ billions)
Exhibit 59: Novo Nordisk: Revenue generated from net product sales of new-generation insulins 2013-2015 ($ millions)
Exhibit 60: Novo Nordisk: YoY growth and revenue of Victoza 2012-2015 ($ billions)
Exhibit 61: Novo Nordisk: YoY growth and revenue of Novonorm, Prandin, and Prandimet 2012-2014 ($ billions)
Exhibit 62: Sanofi: Business segmentation by revenue 2015
Exhibit 63: Sanofi: Profile
Exhibit 64: Sanofi: Strength analysis
Exhibit 65: Sanofi growth strategy matrix
Exhibit 66: Sanofi: Growth opportunity assessment
Exhibit 67: Key product offerings in diabetes market ($ billions)
Exhibit 68: Sanofi: YoY revenue and growth rate of Lantus 2012-2015 ($ billions)
Exhibit 69: Sanofi: YoY revenue and growth rate of Amaryl 2012-2015 ($ billions)
Exhibit 70: Sanofi: YoY revenue and growth rate of Apidra 2012-2015 ($ billions)
Exhibit 71: Sanofi: YoY revenue and growth rate of Insuman 2012-2015 ($ billions)
Exhibit 72: Sanofi: YoY revenue and growth rate of Lyxumia 2013-2015 ($ millions)
Exhibit 73: Sanofi: Revenues of lysosomal storage diseases drugs of Genzyme, 2015
Exhibit 74: Merck: Strength profile
Exhibit 75: Merck: Strength analysis
Exhibit 76: Merck: Growth strategy matrix
Exhibit 77: Merck: Opportunity assessment
Exhibit 78: Top selling diabetes drugs in 2015
Exhibit 79: Merck: Diabetes segmentation by revenue 2015
Exhibit 80: Merck: YoY growth and revenue of Janumet 2012-2015 ($ billions)
Exhibit 81: Merck: YoY growth and revenue of Januvia 2012-2015 ($ billions)
Exhibit 82: Merck: YoY revenue and growth rate of Zetia 2013-2015 ($ billions)
Exhibit 83: Merck: YoY revenue and growth rate of Vytorin 2013-2015 ($ billions)
Exhibit 84: Merck: YoY revenue and growth rate of Zocor 2013-2015 ($ millions)
Exhibit 85: AstraZeneca: Profile
Exhibit 86: AstraZeneca: Strength analysis
Exhibit 87: AstraZeneca: Growth strategy matrix
Exhibit 88: AstraZeneca: Opportunity assessment
Exhibit 89: Top selling diabetes drugs in 2015 ($ billions)
Exhibit 90: AstraZeneca: Byetta YoY growth and revenues 2012-2015 ($ billions)
Exhibit 91: Astrazeneca: Byetta YoY growth rate and revenues in the US ($ billions)
Exhibit 92: AstraZeneca: Bydureon YoY revenues and growth rate 2012-2015 ($ billions)
Exhibit 93: AstraZeneca: Onglyza YoY revenue and growth rate 2012-2015 ($ billions)
Exhibit 94: AstraZeneca: YoY revenue and growth rate of Crestor 2013-2015 ($ billions)
Exhibit 95: AstraZeneca: Geographical segmentation of Crestor 2015 by revenue
Exhibit 96: Eli Lilly: Profile
Exhibit 97: Eli Lilly: Strength analysis
Exhibit 98: Eli Lilly growth strategy matrix
Exhibit 99: Eli Lilly: Opportunity assessment
Exhibit 100: Top selling diabetic drugs 2015 ($ billions)
Exhibit 101: Eli Lilly: YoY revenue and growth rate of Humalog 2012-2015 ($ billions)
Exhibit 102: Eli Lilly: YoY revenue and growth rate of Humulin 2012-2015 ($ billions)
Exhibit 103: Eli Lilly: YoY revenue and growth rate of Tradjenta 2012-2015 ($ billions)
Exhibit 104: Eli Lilly: YoY revenue of Trylicity 2014-2015 ($ millions)
  • Fabry Disease-Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Fabry Disease-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Fabry Disease. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, f......
  • Global Lysosomal Storage Disease Partnering 2010-2016
    Published: 01-Nov-2016        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. • Trends in partnering deals • Top deals by value • Deals listed by company A-Z, industry sector, stage of development, technology type The report provides understandi......
  • Fabry disease - Epidemiology Forecast To 2023
    Published: 01-Nov-2016        Price: US 2750 Onwards        Pages: 60
    DelveInsight "Fabry disease - Epidemiology Forecast To 2023" provides an overview of the epidemiology trends of Fabry disease in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Fabry disease prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need associated with the Fabry dise......
  • Mucopolysaccharidosis - Epidemiology Forecast To 2023
    Published: 01-Nov-2016        Price: US 2750 Onwards        Pages: 60
    DelveInsight "Mucopolysaccharidosis - Epidemiology Forecast To 2023" provides an overview of the epidemiology trends of Mucopolysaccharidosis in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Mucopolysaccharidosis prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need associ......
  • Fabry disease- Market Insights, Epidemiology and Market Forecast-2023
    Published: 01-Nov-2016        Price: US 4950 Onwards        Pages: 100
    DelveInsight's Fabry disease - Market Insights, Epidemiology and Market Forecast-2023" Reports provides an overview of the disease and global market trends of the Indication for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Fabry disease forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includ......
  • Mucopolysaccharidosis-Market Insights, Epidemiology and Market Forecast-2023
    Published: 01-Nov-2016        Price: US 4950 Onwards        Pages: 100
    DelveInsight's Mucopolysaccharidosis - Market Insights, Epidemiology and Market Forecast-2023" Reports provides an overview of the disease and global market trends of the Mucopolysaccharidosis for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Mucopolysaccharidosis forecasted market share for ten years to 2023 segmented by seven major markets. In addit......
  • Lysosomal Storage Disorder-Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Lysosomal Storage Disorder-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Lysosomal Storage Disorder. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, colla......
  • Metabolic Syndrome-Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Metabolic Syndrome-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Metabolic Syndrome. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acqui......
  • Mucopolysaccharidosis-Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Mucopolysaccharidosis-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Mucopolysaccharidosis. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations,......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs